Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 May 31;13(5):909-914.
doi: 10.21037/tau-23-602. Epub 2024 May 16.

About metformin and its action on the mitochondrial respiratory chain in prostate cancer

Affiliations
Editorial

About metformin and its action on the mitochondrial respiratory chain in prostate cancer

Bernard Gallez et al. Transl Androl Urol. .
No abstract available

Keywords: Mitochondria; cancer metabolism; electron transport chain (ETC); metformin; reactive oxygen species (ROS).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-23-602/coif). B.G. and P.S. report the collaborative works of their lab are supported by the Actions de Recherche Concertées program of the Communauté Française de Belgique (ARC 21/26-118). B.G. reports research grants from the Fonds National de la Recherche Scientifique (FNRS) (CDR J.0084.22). B.M. is a Research Fellow of the Belgian Fonds National de la Recherche Scientifique (F.R.S.-FNRS). P.S. reports that he is the inventor of patent application EP21175397.5 “Molecular signature for assessing the responsiveness of cancer to mitochondria-targeted antioxidants” and is involved in a clinical collaboration with Antipodean Pharmaceuticals Inc. for the prevention of breast cancer metastasis; and he is a Research Director of the Belgian Fonds National de la Recherche Scientifique (F.R.S.-FNRS). The authors have no other conflicts of interest to declare.

Figures

Figure 1
Figure 1
Multiple molecular mechanisms of action of metformin on cancer cells. Created with BioRender.com (license to Bernard Gallez). AMPK, AMP-activated protein kinase; ETC, electron transport chain.
Figure 2
Figure 2
Consequences of inhibition of the electron transport chain by metformin on cancer cells. Created with BioRender.com (license to Bernard Gallez). AMPK, AMP-activated protein kinase; TCA, tricarboxylic acid; ROS, reactive oxygen species.

Comment on

  • Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression.
    Papachristodoulou A, Heidegger I, Virk RK, Di Bernardo M, Kim JY, Laplaca C, Picech F, Schäfer G, De Castro GJ, Hibshoosh H, Loda M, Klocker H, Rubin MA, Zheng T, Benson MC, McKiernan JM, Dutta A, Abate-Shen C. Papachristodoulou A, et al. Eur Urol. 2024 Apr;85(4):361-372. doi: 10.1016/j.eururo.2023.07.016. Epub 2023 Aug 31. Eur Urol. 2024. PMID: 37659962 Free PMC article.

Similar articles

Cited by

References

    1. Saraei P, Asadi I, Kakar MA, et al. The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag Res 2019;11:3295-313. 10.2147/CMAR.S200059 - DOI - PMC - PubMed
    1. Margel D, Urbach DR, Lipscombe LL, et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013;31:3069-75. 10.1200/JCO.2012.46.7043 - DOI - PubMed
    1. Patel T, Hruby G, Badani K, et al. Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 2010;76:1240-4. 10.1016/j.urology.2010.03.059 - DOI - PubMed
    1. Morgans AK, Chen YH, Jarrard DF, et al. Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805. Prostate 2022;82:1176-85. 10.1002/pros.24369 - DOI - PMC - PubMed
    1. Papachristodoulou A, Heidegger I, Virk RK, et al. Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression. Eur Urol 2024;85:361-72. 10.1016/j.eururo.2023.07.016 - DOI - PMC - PubMed